Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Thoracic Neuroendocrine Tumors and the Role of Emerging Therapies
share announcement

Thoracic Neuroendocrine Tumors and the Role of Emerging Therapies

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 20 December 2025 | Viewed by 9489

Special Issue Editors

Dr. Nagla Abdel Karim

E-Mail Website
Guest Editor
Inova Schar Cancer Institute, Department of Medicine, University of Virginia, Fairfax, VA 22031, USA
Interests: lung cancer; thoracic oncology; phase I clinical trials/experimental therapeutics
Dr. Asad Ullah

E-Mail Website
Guest Editor
Department of Pathology, Texas Tech University Health Sciences Center, Lubbock, TX, USA
Interests: cancer epidemiology; cancer diagnosis; genomic profiling of cancer; emerging therapies in cancer, neuroendocrine neoplasm; melanoma
Special Issues, Collections and Topics in MDPI journals
Dr. Jaffar Khan

E-Mail Website
Guest Editor
Indiana School of Medicine, Indiana University, Indianapolis, IN, USA
Interests: neuroblastoma; ganglioneuroblastoma; pediatric neck mass; malignancy; neoplasm; pancreas; malignant neoplasm; biphasic; Carcinosarcoma; Pancreatic Ductal Carcinoma; seer; mesothelioma; peritoneal; hipec; radiation; Surgery; Parathyroid carcinoma; seer program; Cancer Staging; incidence; survival; mortality; gist; metastatic gists; MOLECULAR; sdh; dog1; spindle cell tumors; programmed death-ligand; immunosuppression; Autoimmunity; adenocarcinoma
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Fernando Mendes

E-Mail Website
Guest Editor
1. Polytechnic University of Coimbra, Rua da Misericórdia, Lagar dos Cortiços, S. Martinho do Bispo, 3045-093 Coimbra, Portugal
2. H&TRC—Health & Technology Research Center, Coimbra Health School, Polytechnic University of Coimbra, Rua 5 de Outubro, 3045-043 Coimbra, Portugal
3. Biophysics Institute of Faculty of Medicine, Coimbra Institute for Clinical and Biomedical Research (iCBR) Area of Environment Genetics and Oncobiology (CIMAGO), University of Coimbra, 3000-548 Coimbra, Portugal
4. Center for Innovative Biomedicine and Biotechnology, University of Coimbra, 3000-548 Coimbra, Portugal
5. European Association for Professions in Biomedical Sciences, 1000 Brussels, Belgium
Interests: lung cancer; inflammation; radiation effects; immune oncology; biomarkers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Thoracic Neuroendocrine Tumors (NETs) are classified into well-differentiated (low-grade typical carcinoids [TCs] and intermediate-grade atypical carcinoids [ACs]) and poorly differentiated (high-grade large cell neuroendocrine carcinoma LCNEC) or small cell lung carcinoma (SCLC) neuroendocrine carcinoma. Despite the increasing incidence of thoracic NETS, awareness [1] and the development of personalized approach therapies in these patients lag.

Well-differentiated carcinoids, as atypical carcinoid tumors in the lung, can recur and become challenging. Unfortunately, the guidelines regarding adjuvant therapies remain unclear, and current regimens' survival benefit is questionable [2]. There is a critical need to update the classification, diagnosis, and treatment of lung NETs. The development of molecular markers to provide evidence supporting the treatment of this underserved type of NET is an area of unmet need.

Effective systemic therapies for patients with advanced, progressive neuroendocrine lung tumors are very rare. However, recently, everolimus was associated with significant improvement in progression-free survival in patients with progressive lung neuroendocrine tumors [3]. Further drug development is needed.

To date, there is only one biomarker-based clinical trial, S1929, in the poorly differentiated NETs; SCLC that has recently completed enrollment for screening, that attempts to stratify patients with SCLC to receive PARP inhibitor based on SLFN11 that is expressed by more than half of patients with SCLC. Further knowledge of predictive factors and novel therapies is needed.

References:

  1. Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease. Hendifar, Marchevsky, and Tuli. Journal of Thoracic Oncology Vol. 12 No. 3: 425–436.
  2. Survival Benefit of Adjuvant Chemotherapy in Pulmonary Carcinoid: A systematic Review. Philip Sobash and Nagla Abdel Karim. NCCN Virtual Annual Conference 2021 General Poster Session.
  3. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Yao, Fazio, Singh et. al. The Lancet. Volume 387, Issue 10022, 5–11 March 2016, Pages 968–977.

Dr. Nagla Abdel Karim
Dr. Asad Ullah
Dr. Jaffar Khan
Prof. Dr. Fernando Mendes
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • thoracic neuroendocrine tumors
  • lung NETs
  • low-grade typical carcinoids
  • TCs
  • intermediate-grade atypical carcinoids
  • ACs
  • high-grade large cell neuroendocrine carcinoma LCNEC
  • small cell lung carcinoma (SCLC) neuroendocrine carcinoma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 2574 KiB  
Article
Treatment, Prognostic Markers, and Survival in Thymic Neuroendocrine Tumors, with Special Reference to Temozolomide-Based Chemotherapy
by Zixuan Cheng, Fuhuan Yu, Ruao Chen, Lingjun Cui, Yingying Chen, Chao Deng, Yanfen Shi and Huangying Tan
Cancers 2024, 16(14), 2502; https://doi.org/10.3390/cancers16142502 - 10 Jul 2024
Viewed by 1353
Abstract
Background: Thymic neuroendocrine tumors (Th-NETs) are rare and aggressive, with a scarcity of research on predicting patient prognosis. Our study aimed to assess the impact of prognostic markers and temozolomide (TMZ)-based chemotherapy on survival in Th-NETs. Methods: We retrospectively reviewed the medical records [...] Read more.
Background: Thymic neuroendocrine tumors (Th-NETs) are rare and aggressive, with a scarcity of research on predicting patient prognosis. Our study aimed to assess the impact of prognostic markers and temozolomide (TMZ)-based chemotherapy on survival in Th-NETs. Methods: We retrospectively reviewed the medical records of patients diagnosed with Th-NETs between 2013 and 2023 at our institution. We collected clinicopathological data, including tumor pathological grading, staging, serum concentrations of neuron-specific enolase (NSE) and pro-gastrin-releasing peptide, levels of inflammatory factors, and expression of oxygen 6-methylguanine-DNA methyltransferase (MGMT). Treatment details (such as surgery and chemotherapy) and survival outcomes were also documented. Results: A total of 32 patients were included in our study after excluding those without complete available information. The median progression-free survival (PFS) was 12.5 months (95%CI, 8–16 months) for 19 patients who received TMZ-based chemotherapy. Twenty-one patients underwent surgery as the primary treatment, demonstrating a median disease-free survival (DFS) of 51.0 months. The inflammatory factor neutrophil-to-lymphocyte ratio (NLR) was an independent prognostic indicator of DFS in postoperative patients and PFS in TMZ-treated patients. The overall 3-, 5-, and 10-year survival rates were 86.6%, 69.5%, and 33.8%, respectively. Ki67 level exceeding 10% (p = 0.048) and absence of surgical resection (p = 0.003) were significantly associated with worse overall survival (OS). Conclusion: Surgical treatment was currently the primary method for treating Th-NETs, and postoperative adjuvant therapy was an essential consideration for specific patient cohorts. Despite widespread positive MGMT expression, TMZ-based chemotherapy showed promise. Some potential prognostic biomarkers such as NLR and NSE need more attention. Full article
(This article belongs to the Special Issue Thoracic Neuroendocrine Tumors and the Role of Emerging Therapies)
►▼ Show Figures

Figure 1

10 pages, 491 KiB  
Article
Pro-Gastrin-Releasing Peptide as a Biomarker in Lung Neuroendocrine Neoplasm
by Violetta Rosiek, Angelika Kogut and Beata Kos-Kudła
Cancers 2023, 15(13), 3282; https://doi.org/10.3390/cancers15133282 - 22 Jun 2023
Cited by 7 | Viewed by 2134
Abstract
There is a lack of effective biomarkers for diagnosing lung neuroendocrine neoplasms (LNENs). A known small cell lung cancer (SCLC) biomarker is a pro-gastrin-releasing peptide (ProGRP), but not for all LNENs, especially for bronchopulmonary carcinoids. This study aimed to evaluate the diagnostic value [...] Read more.
There is a lack of effective biomarkers for diagnosing lung neuroendocrine neoplasms (LNENs). A known small cell lung cancer (SCLC) biomarker is a pro-gastrin-releasing peptide (ProGRP), but not for all LNENs, especially for bronchopulmonary carcinoids. This study aimed to evaluate the diagnostic value of ProGRP and chromogranin A (CgA) in diagnosing LNENs. The ProGRP and CgA levels in 290 cases of LNENs and 54 healthy controls (HCs) were measured. The median ProGRP concentration in the group of LNEN patients was 136.4 pg/mL, higher than that of HCs at 6.5 pg/mL. Most of the LNEN cohort was well-differentiated tumors (typical and atypical carcinoids, n = 262, 91.7% of all LNENs). The sensitivity, specificity, and area under the curve (AUC) of ProGRP when distinguishing LNENs vs. HCs were 94.8%, 100%, and 0.995. CgA (AUC = 0.375) could not determine LNENs vs. HCs. Therefore, based on these results, ProGRP may be considered as an effective marker for diagnosing LNENs. Full article
(This article belongs to the Special Issue Thoracic Neuroendocrine Tumors and the Role of Emerging Therapies)
►▼ Show Figures

Figure 1

13 pages, 1360 KiB  
Article
Demographics and Clinicopathologic Profile of Pulmonary Sarcomatoid Carcinoma with Survival Analysis and Genomic Landscape
by Asad Ullah, Asim Ahmed, Abdul Qahar Khan Yasinzai, Kue Tylor Lee, Israr Khan, Bina Asif, Imran Khan, Bisma Tareen, Kaleemullah Kakar, Gul Andam, Saleh Heneidi, Jaffar Khan, Hina Khan, Nabin R. Karki, Jaydira Del Rivero and Nagla Abdel Karim
Cancers 2023, 15(9), 2469; https://doi.org/10.3390/cancers15092469 - 26 Apr 2023
Cited by 2 | Viewed by 2746
Abstract
Background: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer (NSCLC) with an aggressive clinical nature and poor prognosis. With novel targeted therapeutics being developed, new ways to effectively treat PSC are emerging. In this study, we analyze demographics, [...] Read more.
Background: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer (NSCLC) with an aggressive clinical nature and poor prognosis. With novel targeted therapeutics being developed, new ways to effectively treat PSC are emerging. In this study, we analyze demographics, tumor characteristics, treatment modalities, and outcomes of PSC and genetic mutations in PSC. Methods: Data from the Surveillance, Epidemiology, and End Results (SEER) database were reviewed to analyze cases of pulmonary sarcomatoid carcinoma from 2000 to 2018. The molecular data with the most common mutations in PSC were extracted from the Catalogue Of Somatic Mutations in Cancer (COSMIC) database. Results: A total of 5259 patients with PSC were identified. Most patients were between 70 and 79 years of age (32.2%), male (59.1%), and Caucasian (83.7%). The male-to-female ratio was 1.45:1. Most tumors were between 1 and 7 cm in size (69.4%) and poorly differentiated (grade III) (72.9%). The overall 5-year survival was 15.6% (95% confidence interval (95% CI) = 14.4–16.9)), and the cause-specific 5-year survival was 19.7% (95% CI = 18.3–21.1). The five-year survival for those treated with each modality were as follows: chemotherapy, 19.9% (95% CI = 17.7–22.2); surgery, 41.7% (95% CI = 38.9–44.6); radiation, 19.1% (95% CI = 15.1–23.5); and multimodality therapy (surgery and chemoradiation), 24.8% (95% CI = 17.6–32.7). On multivariable analysis, age, male gender, distant stage, tumor size, bone metastasis, brain metastasis, and liver metastasis were associated with increased mortality, and chemotherapy and surgery were associated with reduced mortality (p < 0.001). The best survival outcomes were achieved with surgery. The most common mutations identified in COSMIC data were TP53 31%, ARID1A 23%, NF1 17%, SMARCA4 16%, and KMT2D 9%. Conclusions: PSC is a rare and aggressive subtype of NSCLC, usually affecting Caucasian males between 70 and 79. Male gender, older age, and distant spread were associated with poor clinical outcomes. Treatment with surgery was associated with better survival outcomes. Full article
(This article belongs to the Special Issue Thoracic Neuroendocrine Tumors and the Role of Emerging Therapies)
►▼ Show Figures

Figure 1

16 pages, 3776 KiB  
Article
The Role of Surgery in Primary Chest Wall Tumors: Over 20 Years’ Experience in Resection and Reconstruction
by Giorgio Lo Iacono, Antonio Mazzella, Shehab Mohamed, Francesco Petrella, Giulia Sedda, Monica Casiraghi, Lara Girelli, Luca Bertolaccini and Lorenzo Spaggiari
Cancers 2023, 15(7), 2153; https://doi.org/10.3390/cancers15072153 - 5 Apr 2023
Cited by 8 | Viewed by 2227
Abstract
Background: Primary chest wall tumors comprise a heterogeneous group of neoplasms arising from soft tissues and bones. While surgical excision is the standard of care for benign tumors, the management of malignant tumors requires multimodal treatment. We conducted a predictive analysis of outcome, [...] Read more.
Background: Primary chest wall tumors comprise a heterogeneous group of neoplasms arising from soft tissues and bones. While surgical excision is the standard of care for benign tumors, the management of malignant tumors requires multimodal treatment. We conducted a predictive analysis of outcome, recurrence-free and overall survival. Methods: We retrospectively reviewed the clinical and pathological records of all patients treated in our center between 1998 and 2020. Results: 53 patients (15–85 years) were treated in our department. The average tumor diameter was 65 ± 35 mm (10–160 mm). Negative margins were obtained in 48 patients (90.6%), whereas in the remaining 5, R1 resection was accomplished. Median overall survival was 63,03 months (1–282 months). Overall survival was 90% at 1 year, 78% at 2 years, and 61% at 5 years. Our analysis identified tumor diameter, postoperative complications, and high grade of malignancy as factors that can influence prognosis. Conclusions: The treatment of primary chest wall tumors remains a very challenging process. Different histological types preclude definition of an unequivocal approach. Complete resection with healthy margins remains a definitive cornerstone in the treatment of these cancers as part of a more comprehensive approach. Full article
(This article belongs to the Special Issue Thoracic Neuroendocrine Tumors and the Role of Emerging Therapies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop